The clinical goal for prescribing exercise dictates the regimen. A prescription for managing treatment-related fatigue will differ significantly from one intended as a direct anti-cancer therapy or for preventing long-term cardiometabolic disease. The type, dose, and intensity must match the specific indication.

The CHALENSE study demonstrated that a structured exercise program after adjuvant chemotherapy improved disease-free and overall survival in colon cancer patients. The magnitude of this benefit is comparable to that of established chemotherapy drugs like oxaliplatin, making exercise a critical, non-pharmacological standard of care.

Survey data reveals extreme heterogeneity in patient risk tolerance for adjuvant chemotherapy. A significant cohort, about one-third, would endure treatment for a minimal 1% improvement in survival, while a smaller group of 10-15% would decline it even for a 10% absolute benefit. This underscores the importance of personalized, value-based discussions.

Generic advice like "diet and exercise" is ineffective for cancer patients. Clinicians should adopt a pharmaceutical model, prescribing specific types and "doses" of diet and exercise based on a patient's unique metabolic profile, treatment, and clinical goals, rather than handing out a generic brochure.

The practice-changing DYNAMIC trial showed that a ctDNA-guided strategy for stage II colorectal cancer reduces adjuvant chemotherapy use by 50%. Despite this significant de-escalation of treatment, patient outcomes and survival rates were identical to the standard-of-care approach.

Data from the CO21 trial shows a structured exercise program provides a 7% improvement in overall survival for high-risk colon cancer patients. This non-pharmacological intervention demonstrates a greater survival benefit than the established 5% gain from adding oxaliplatin to chemotherapy.

A post-hoc analysis found celecoxib, which showed no overall benefit, nearly doubled 3-year disease-free survival (22% to 41%) specifically in patients who were ctDNA-positive after completing adjuvant therapy. This compelling, hypothesis-generating data suggests a targeted role for a common anti-inflammatory drug in the highest-risk population.

A meta-analysis of over 3,000 patients shows that neoadjuvant chemotherapy for MSS colon cancer provides a 5% improvement in survival. This benefit is clinically meaningful and equivalent in magnitude to the landmark addition of oxaliplatin to 5-FU in the original MOSAIC trial.

Observational data from the BESPOKE study showed that the survival benefit from adjuvant chemotherapy was only seen in patients who tested positive for ctDNA post-surgery. In contrast, ctDNA-negative patients had overlapping survival curves whether they received chemotherapy or not, questioning its utility for that group.